RUNX1

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Retrieved on: 
Thursday, March 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapy, NSCLC, Investigational New Drug, Bone marrow, AML, RUNX1, Cancer, B-cell lymphoma, ASXL1, Clinical Cancer Research, Classification, Patient, CERO, IND, Cero, Vaccine

The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.

Key Points: 
  • The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.
  • Finally, the target for CER-1236 was found by CERo to be highly expressed and detectable across common AML genetic classification subtypes, including patient samples with adverse risk mutations in TP53, ASXL1 and RUNX1.
  • “We’re very pleased with this publication in Clinical Cancer Research supporting our near term plans to advance CER-1236 into the clinic.
  • As we have previously reported, CERo plans to file an Investigational New Drug (IND) application in the first half of 2024, and is targeting initial treatment of AML patients as well as B Cell lymphoma patients before the end of the year,” said Brian G Atwood, CERo’s Chairman and Chief Executive Officer.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, International Prognostic Scoring System, IPSS, Survival, FDA, RUNX1, H. Lee Moffitt Cancer Center & Research Institute, VAF, Food, TP53, Thrombocytopenia, Literature, EZH2, MDS, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Imetelstat, Society, ASXL1, SF3B1, Transfusion-dependent anemia, Geron Corporation, Risk, Abstract, TI, EMA, Corporation, LR, Anemia, ETV6, Patient, Neutropenia, Mutation, Pharmaceutical industry, Communications satellite, ASH

Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.

Key Points: 
  • Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
  • “Additionally, our abstract showcasing a real-world data population level analysis of over 5,000 lower risk MDS patients adds to the significant literature suggesting a correlation between TI and improvement in survival.
  • This analysis suggests imetelstat has clinical activity in lower risk MDS patients independent of risk categories.
  • Achievement of durable TI was associated with improved survival, supporting the clinical benefit of achieving transfusion independence in lower risk MDS.

Aptose Reports Results for the First Quarter 2023

Retrieved on: 
Monday, May 8, 2023
TP53, APS, CRH, NPM1, Aes, Food and Drug Administration, Clinical trial, G1, Absorption, Aplastic anemia, Trial of the century, Acute myeloid leukemia, Phase 1, AML, Running, Drug-related deaths in the United Kingdom, MLL, Patient, RAS, SAN, EHA, RUNX1, IDH, FLT3, TSX, CRi, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, FDA, CRP, Gene, Safety, Pharmaceutical industry, DNMT3A, G3

─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;

Key Points: 
  • ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;
    SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for first quarter ended March 31, 2023, and provided a corporate update.
  • “While it is still too early to report confirmed responses in the APTIVATE trial, it is moving in the right direction.
  • Aptose has identified a safe therapeutic range with a broad therapeutic window, spanning the dose levels of 40, 80, 120 and 160 milligrams.
  • If findings continue as anticipated, Aptose plans to escalate the dose of G3 and seek a dose with robust safety and higher exposure levels.

Einstein, Montefiore, and Lehman College Launch New M.S. Program in Biological Sciences

Retrieved on: 
Thursday, May 4, 2023
Albert Einstein College of Medicine, Translation, Albert Einstein, DNA, CUNY, Cell biology, Student, Biochemistry, Harold, Doctor of Philosophy, MECC, Lehman College, Hunter College, Malaria, Research, Medicine, Mentorship, Lehman, National Institutes of Health, Bangladesh Technical Education Board, Science, Akua, Master of Science, American Society of Tropical Medicine and Hygiene, DNA repair, Montefiore Medical Center, Laboratory, Tropical medicine, OTR/L, RUNX1, Biology, Knowledge, Alex's Lemonade Stand Foundation, City, Hygiene, Leukemia, NCI, ICTR, City University, Management, Nursing, Pharmaceutical industry, Discover

BRONX, N.Y., May 4, 2023 /PRNewswire/ -- Albert Einstein College of Medicine and Montefiore Health System have announced a collaboration with Lehman College of the City University of New York (CUNY) to launch the Einstein Discover Research Program .

Key Points: 
  • BRONX, N.Y., May 4, 2023 /PRNewswire/ -- Albert Einstein College of Medicine and Montefiore Health System have announced a collaboration with Lehman College of the City University of New York (CUNY) to launch the Einstein Discover Research Program .
  • The Discover Program immerses students in research, incorporating them into laboratory teams with National Institutes of Health-funded investigators, postgraduate fellows, Ph.D. students, and lab technicians.
  • CUNY Lehman College, a Bronx-based, minority-serving institution, currently offers a Master of Arts (M.A.)
  • Current and incoming students at Lehman College may apply to the program.

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Thursday, March 23, 2023
ASH, Lux, APS, Controller, ITD, TKD, G1, BCR, Associate, Accounting, Plasma, RAS, Investment, Patient, RUNX1, Clinical, LYN, TP53, DNMT3A, SYK, European Hematology Association, Research, Aplastic anemia, MRD, BCL2, PLOS One, MLL, Data, FLT3, TSX, Amylin Pharmaceuticals, FDA, Combination, RSK, Lymphoid leukemia, Absorption, BTK, Acute myeloid leukemia, Phase 1, CR, Hand, MD Anderson Cancer Center, Inflammation, Lymphoma, Phosphorylation, National university, NPM1, Clinical trial, European School, Data monitoring committee, AML, BID, EHA, ISTA Pharmaceuticals, Harvard Business School, Toxic leukoencephalopathy, G3, Gene, Society, Pharmaceutical industry, Cryptocurrency, Vaccine, Running

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  • Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million.
  • Aptose Appoints VP, Controller – During the fourth quarter, Aptose appointed Brooks Ensign, Vice President and Controller.
  • A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

Retrieved on: 
Monday, January 30, 2023
AML, Gene, BCL2, Society, ASH, NRAS, ITD, MLL, TSX, Mutation, SYK, Aplastic anemia, Toxic leukoencephalopathy, Patient, SAN, Clinical trial, NPM1, FDA, MD Anderson Cancer Center, KRAS, RUNX1, TKD, Acute myeloid leukemia, APS, TP53, FLT3, Toxicity, Maintenance, Associate, TKI, Pharmaceutical industry, Vaccine, DNMT3A

SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML). In parallel, another clinical response has been achieved by a R/R AML patient receiving 40 mg tuspetinib once daily orally in the original dose exploration trial, the second response at the recently launched low-dose 40 mg cohort.

Key Points: 
  • SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
  • Importantly, Aptose has elucidated a rationale for the superior safety profile of tuspetinib.
  • In the APTIVATE expansion trial, tuspetinib also will be tested in combination with venetoclax.
  • “We are pleased to have dosing underway in our APTIVATE clinical trial of tuspetinib in a very ill R/R AML population,” said William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer.

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Retrieved on: 
Sunday, December 11, 2022
Associate, NRAS, HSCT, Absorption, MLL, ASH, Infrared spectroscopy correlation table, FLT3, RUNX1, AML, Toxicity, ITD, Gene, Research, PR, COVID-19, KRAS, Clinical trial, Aplastic anemia, Safety, Bone marrow, B-cell lymphoma, Drug development, Risk, MRD, TSX, Solar cycle 22, Society, Plasma, CRC, Hematology, APS, SYK, JAK, Animal, BID, TP53, Exchange, BTK, Prior, Patient, MD Anderson Cancer Center, NPM1, GMP, AES, Toxic leukoencephalopathy, CR, Acute myeloid leukemia, TKD, G1, DLBCL, Pharmaceutical industry, Dietary supplement, Generic drug, DNMT3A, G3

“The welcome blend of safety and breadth of activity seen with tuspetinib in AML patients makes this an ideal candidate for combination therapy,” remarked Dr. Daver.

Key Points: 
  • “The welcome blend of safety and breadth of activity seen with tuspetinib in AML patients makes this an ideal candidate for combination therapy,” remarked Dr. Daver.
  • Prior to Aptose licensing tuspetinib, Hanmi Pharmaceutical Company demonstrated complete remissions at the 80 mg dose level.
  • As of January 1, 2022, Aptose assumed control of clinical trial activities and has demonstrated additional complete remissions at the 120 mg, 160 mg, and now the 40 mg dose levels.
  • Vignettes of patient experiences highlight the potency and breadth of tuspetinib to deliver complete remissions among several mutationally-defined populations with a diversity of adverse mutations.

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Monday, December 12, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Leukemia Research, HOXA9, Lymphatic system, CEBPA, Software, Biosimulation, Society, Research, Methylation, Disease, Patient, DS, SPI1, Pearson, EZH2, Myelodysplastic syndrome, AML, MDS, Drug combination, Prognosis, Decitabine, City, University of Tennessee Health Science Center, University, DNMT3A, Abstract, Survival, NR, R, MD, Leukemia, Diagnosis, CBL, CBM, UnitedHealth Group, Student, TP53, Sequoia Capital, HMA, ASH, Versata Development Group, Inc. v. SAP America, Inc., Master of Science, Exposition, Chair, NF1, ITGAM, Haematopoietic system, Biomarker, RUNX1, Neuro, GATA1, Blood, Hypomethylating agent, NRAS, Medical imaging, Pharmaceutical industry, Hematology

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.

Aptose Reports Results for the Third Quarter 2022

Retrieved on: 
Tuesday, November 1, 2022
APS, TP53, Plasma, Venetoclax, Continuity, KRAS, GLOBE, Research, ASH, Bioavailability, Absorption, TSX, NRAS, NPM1, AML, Investment, NASDAQ, G1, Hand, Company, FDA, RUNX1, Patient, Acute myeloid leukemia, Exploration, USAN, PTPN11, Gene, Pharmaceutical industry, G3, FLT3, DNMT3A

SAN DIEGO and TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three and nine-month periods ended September 30, 2022 and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.
  • Total cash and cash equivalents and investments as of September 30, 2022 were $55.4 million.
  • Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development into the first quarter of 2024.
  • A summary of the results of operations for the three and nine-month periods ended September 30, 2022 and 2021 is presented below:

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Retrieved on: 
Thursday, May 19, 2022
Cancer, Diabetes, Acute myeloid leukemia, Risk, Osteopathic medicine in Canada, Disease management, Toxic leukoencephalopathy, NPM1, U.S. Securities and Exchange Commission, Survival, Nasdaq, FLT3, IC50, AML, Patient, RAS, RUNX1, KIT, RTK, Lists of diseases, Securities Exchange Act of 1934, Gene family, Research, FDA, DNMT3A, Securities Act of 1933, IND, Board, III, Standard of care, Drug Quality and Security Act, Aplastic anemia, Mutation, SEC, Cell cycle, GLOBE, Pharmaceutical industry, Fine chemical

Approximately 30% of AML patients present with a FLT3 mutation and remain poorly controlled with currently available therapies.

Key Points: 
  • Approximately 30% of AML patients present with a FLT3 mutation and remain poorly controlled with currently available therapies.
  • BMF-500 was discovered and developed in-house at Biomea using the companys proprietary FUSION System.
  • Specifically, BMF-500 was observed in preclinical studies to be a highly active inhibitor of FLT3 with picomolar affinity for key isoforms of FLT3 while avoiding other key kinases tested, including structurally related KIT.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.